Animal and human studies suggest that the pneumococcal vaccine may protect against, or even reverse, a build-up of fatty materials inside the arteries. This build-up can lead to heart attack or stroke. You have the opportunity to participate in a world-first study to determine whether the pneumococcal vaccine reduces the risk of heart attack and stroke.
Half the participants will be given the pneumococcal vaccine (an existing vaccine originally developed for pneumococcal pneumonia) and the other half will be given a placebo vaccine (saline). Patients won’t be told which group they are in, and data from their health records will be used to track cardiovascular and other health.
Find out more here: Information Statement
Sign up now